Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies

Current Cancer Drug Targets

Volumn 11, Issue 6, 2011, Pages 714-733

  Wiedmann, M W ^a,b   Mossner J ^b  

^a St Mary's Hospital   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Hepatocellular carcinoma; Molecular targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

BEVACIZUMAB; BRIVANIB ALANINATE; CAPECITABINE; CEDIRANIB; CELGENE; CETUXIMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; IMATINIB; IMC 1121 B; LAPATINIB; LETROZOLE; LINIFANIB; OCTREOTIDE; ORANTINIB; OXALIPLATIN; RAMUCIRUMAB; RAPAMYCIN; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIVANTINIB; TRASTUZUMAB; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; BACKACHE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC EOSINOPHILIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEUKEMIA; LEUKOPENIA; LIVER ABSCESS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALAISE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THROMBOSIS; TRANSGENIC MOUSE; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; WOUND INFECTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959929521     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911796191033     Document Type: Article

References (140)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
2. Lesurtel, M.; Mullhaupt, B.; Pestalozzi, B. C.; Pfammatter, T.; Clavien, P. A. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am. J. Transplant. 2006, 6, 2644-2650.
3. Mazzaferro, V.; Romito, R.; Schiavo, M.; Mariani, L.; Camerini, T.; Bhoori, S.; Capussotti, L.; Calise, F.; Pellicci, R.; Belli, G.; Tagger, A.; Colombo, M.; Bonino, F.; Majno, P.; Llovet, J. M. Prevention of hepatocellular carcinoma recurrence with alphainterferon after liver resection in HCV cirrhosis. Hepatology 2006, 44, 1543-1554.
4. Lo, C. M.; Liu, C. L.; Chan, S. C.; Lam, C. M.; Poon, R. T.; Ng, I. O.; Fan, S. T.; Wong, J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann. Surg. 2007, 245, 831-842.
5. Muto, Y.; Moriwaki, H.; Ninomiya, M.; Adachi, S.; Saito, A.; Takasaki, K. T.; Tanaka, T.; Tsurumi, K.; Okuno, M.; Tomita, E.; Nakamura, T.; Kojima, T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 1996, 334, 1561-1567.
6. Lau, W. Y.; Leung, T. W.; Ho, S. K.; Chan, M.; Machin, D.; Lau, J.; Chan, A. T.; Yeo, W.; Mok, T. S.; Yu, S. C.; Leung, N. W.; Johnson, P. J. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999, 353, 797-801.
7. Kuang, M.; Peng, B. G.; Lu, M. D.; Liang, L. J.; Huang, J. F.; He, Q.; Hua, Y. P.; Totsuka, S.; Liu, S. Q.; Leong, K. W.; Ohno, T. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin. Cancer Res. 2004, 10, 1574-1579.
8. Takayama, T.; Sekine, T.; Makuuchi, M.; Yamasaki, S.; Kosuge, T.; Yamamoto, J.; Shimada, K.; Sakamoto, M.; Hirohashi, S.; Ohashi, Y.; Kakizoe, T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000, 356, 802-807.
9. Llovet, J. M.; Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37, 429-442.
10. Ng, I. O.; Liu, C. L.; Fan, S. T.; Ng, M. Expression of Pglycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am. J. Clin. Pathol. 2000, 113, 355-363.
11. Yeo, W.; Mok, T. S.; Zee, B.; Leung, T. W.; Lai, P. B.; Lau, W. Y.; Koh, J.; Mo, F. K.; Yu, S. C.; Chan, A. T.; Hui, P.; Ma, B.; Lam, K. C.; Ho, W. M.; Wong, H. T.; Tang, A.; Johnson, P. J. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 2005, 97, 1532-1538.
12. Lai, C. L.; Wu, P. C.; Chan, G. C.; Lok, A. S.; Lin, H. J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988, 62, 479-483.
13. Choi, T. K.; Lee, N. W.; Wong, J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 1984, 53, 401-405.
14. Nowak, A. K.; Stockler, M. R.; Chow, P. K.; Findlay, M. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Cancer 2005, 103, 1408-1414.
15. Villa, E.; Ferretti, I.; Grottola, A.; Buttafoco, P.; Buono, M. G.; Giannini, F.; Manno, M.; Bertani, H.; Dugani, A.; Manenti, F. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br. J. Cancer 2001, 84, 881-885.
16. Grimaldi, C.; Bleiberg, H.; Gay, F.; Messner, M.; Rougier, P.; Kok, T. C.; Cirera, L.; Cervantes, A.; De Greve, J.; Paillot, B.; Buset, M.; Nitti, D.; Sahmoud, T.; Duez, N.; Wils, J. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J. Clin. Oncol. 1998, 16, 411-417.
17. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004, 40, 1361-1369.
18. Kouroumalis, E.; Skordilis, P.; Thermos, K.; Vasilaki, A.; Moschandrea, J.; Manousos, O. N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998, 42, 442-447.
19. Barbare, J. C.; Bouche, O.; Bonnetain, F.; Dahan, L.; Lombard-Bohas, C.; Faroux, R.; Raoul, J. L.; Cattan, S.; Lemoine, A.; Blanc, J. F.; Bronowicki, J. P.; Zarski, J. P.; Cazorla, S.; Gargot, D.; Thevenot, T.; Diaz, E.; Bastie, A.; Aparicio, T.; Bedenne, L. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur. J. Cancer 2009, 45, 1788-1797.
20. Becker, G.; Allgaier, H. P.; Olschewski, M.; Zahringer, A.; Blum, H. E. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007, 45, 9-15.
21. Verset, G.; Verslype, C.; Reynaert, H.; Borbath, I.; Langlet, P.; Vandebroek, A.; Peeters, M.; Houbiers, G.; Francque, S.; Arvanitakis, M.; Van Laethem, J. L. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br. J. Cancer 2007, 97, 582-588.
22. Dalhoff, K.; Dancey, J.; Astrup, L.; Skovsgaard, T.; Hamberg, K. J.; Lofts, F. J.; Rosmorduc, O.; Erlinger, S.; Bach Hansen, J.; Steward, W. P.; Skov, T.; Burcharth, F.; Evans, T. R. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 2003, 89, 252-257.
23. Kawata, S.; Yamasaki, E.; Nagase, T.; Inui, Y.; Ito, N.; Matsuda, Y.; Inada, M.; Tamura, S.; Noda, S.; Imai, Y.; Matsuzawa, Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 2001, 84, 886-891.
24. Glazer, E. S.; Piccirillo, M.; Albino, V.; Di Giacomo, R.; Palaia, R.; Mastro, A. A.; Beneduce, G.; Castello, G.; De Rosa, V.; Petrillo, A.; Ascierto, P. A.; Curley, S. A.; Izzo, F. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J. Clin. Oncol. 2010, 28, 2220-2226.
25. Kulik, L. M.; Carr, B. I.; Mulcahy, M. F.; Lewandowski, R. J.; Atassi, B.; Ryu, R. K.; Sato, K. T.; Benson, A., 3rd; Nemcek, A. A., Jr.; Gates, V. L.; Abecassis, M.; Omary, R. A.; Salem, R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008, 47, 71-81.
26. Villanueva, A.; Newell, P.; Chiang, D. Y.; Friedman, S. L.; Llovet, J. M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 2007, 27, 55-76.
27. Rygaard, J.; Povlsen, C. O. Heterotransplantation of a human malignant tumour to Nude mice. Acta Pathol. Microbiol. Scand. 1969, 77, 758-760.
28. Frese, K. K.; Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7, 645-658.
29. Baron, U.; Bujard, H. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol. 2000, 327, 401-421.
30. Fausto, N.; Campbell, J. S. Mouse models of hepatocellular carcinoma. Semin. Liver Dis. 2010, 30, 87-98.
31. Ullrich, A.; Coussens, L.; Hayflick, J. S.; Dull, T. J.; Gray, A.; Tam, A. W.; Lee, J.; Yarden, Y.; Libermann, T. A.; Schlessinger, J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309, 418-425.
32. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
33. Raymond, E.; Faivre, S.; Armand, J. P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000, 60 Suppl 1, 15-23; discussion 41-42.
34. Laskin, J. J.; Sandler, A. B. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev. 2004, 30, 1-17.
35. Ritter, C. A.; Arteaga, C. L. The epidermal growth factor receptortyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 2003, 30, 3-11.
36. Hackel, P. O.; Zwick, E.; Prenzel, N.; Ullrich, A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 1999, 11, 184-189.
37. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
38. Rak, J.; Yu, J. L.; Klement, G.; Kerbel, R. S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc. 2000, 5, 24-33.
39. Wiedmann, M. W.; Caca, K. Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets 2005, 5, 171-193.
40. Baselga, J.; Arteaga, C. L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005, 23, 2445-2459.
41. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358, 1160-1174.
42. Ito, Y.; Takeda, T.; Higashiyama, S.; Sakon, M.; Wakasa, K. I.; Tsujimoto, M.; Monden, M.; Matsuura, N. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol. Rep. 2001, 8, 903-907.
43. Yeh, Y. C.; Tsai, J. F.; Chuang, L. Y.; Yeh, H. W.; Tsai, J. H.; Florine, D. L.; Tam, J. P. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alphafetoprotein levels in patients with hepatocellular carcinoma. Cancer Res. 1987, 47, 896-901.
44. Carlin, C. R.; Simon, D.; Mattison, J.; Knowles, B. B. Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol. Cell. Biol. 1988, 8, 25-34.
45. Kira, S.; Nakanishi, T.; Suemori, S.; Kitamoto, M.; Watanabe, Y.; Kajiyama, G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 1997, 17, 177-182.
46. Kiss, A.; Wang, N. J.; Xie, J. P.; Thorgeirsson, S. S. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin. Cancer Res 1997, 3, 1059-1066.
47. Harada, K.; Shiota, G.; Kawasaki, H. Transforming growth factoralpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999, 19, 318-325.
48. Morimitsu, Y.; Hsia, C. C.; Kojiro, M.; Tabor, E. Nodules of lessdifferentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum. Pathol. 1995, 26, 1126-1132.
49. Yamaguchi, K.; Carr, B. I.; Nalesnik, M. A. Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J. Surg. Oncol. 1995, 58, 240-245.
50. Ito, Y.; Takeda, T.; Sakon, M.; Tsujimoto, M.; Higashiyama, S.; Noda, K.; Miyoshi, E.; Monden, M.; Matsuura, N. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 2001, 84, 1377-1383.
51. Altimari, A.; Fiorentino, M.; Gabusi, E.; Gruppioni, E.; Corti, B.; D'Errico, A.; Grigioni, W. F. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig. Liver Dis. 2003, 35, 332-338.
52. Nakopoulou, L.; Stefanaki, K.; Filaktopoulos, D.; Giannopoulou, I. C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study. Histol. Histopathol. 1994, 9, 677-682.
53. Niu, Z. S.; Wang, M. Expression of c-erbB-2 and glutathione Stransferase-pi in hepatocellular carcinoma and its adjacent tissue. World J. Gastroenterol. 2005, 11, 4404-4408.
54. Xian, Z. H.; Zhang, S. H.; Cong, W. M.; Wu, W. Q.; Wu, M. C. Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J. Clin. Pathol. 2005, 58, 500-503.
55. Vlasoff, D. M.; Baschinsky, D. Y.; De Young, B. R.; Morrison, C. D.; Nuovo, G. J.; Frankel, W. L. C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms. Appl. Immunohistochem. Mol. Morphol. 2002, 10, 237-241.
56. Hsu, C.; Huang, C. L.; Hsu, H. C.; Lee, P. H.; Wang, S. J.; Cheng, A. L. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 2002, 94, 415-420.
57. Collier, J. D.; Guo, K.; Mathew, J.; May, F. E.; Bennett, M. K.; Corbett, I. P.; Bassendine, M. F.; Burt, A. D. C-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J. Hepatol. 1992, 14, 377-380.
58. Philip, P. A.; Mahoney, M. R.; Allmer, C.; Thomas, J.; Pitot, H. C.; Kim, G.; Donehower, R. C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 2005, 23, 6657-6663.
59. Thomas, M. B.; Chadha, R.; Glover, K.; Wang, X.; Morris, J.; Brown, T.; Rashid, A.; Dancey, J.; Abbruzzese, J. L. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007, 110, 1059-1067.
60. Thomas, M. B.; Morris, J. S.; Chadha, R.; Iwasaki, M.; Kaur, H.; Lin, E.; Kaseb, A.; Glover, K.; Davila, M.; Abbruzzese, J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 2009, 27, 843-850.
61. Desbois-Mouthon, C.; Cacheux, W.; Blivet-Van Eggelpoel, M. J.; Barbu, V.; Fartoux, L.; Poupon, R.; Housset, C.; Rosmorduc, O. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int. J. Cancer 2006, 119, 2557-2566.
62. Zhu, A. X.; Stuart, K.; Blaszkowsky, L. S.; Muzikansky, A.; Reitberg, D. P.; Clark, J. W.; Enzinger, P. C.; Bhargava, P.; Meyerhardt, J. A.; Horgan, K.; Fuchs, C. S.; Ryan, D. P. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007, 110, 581-589.
63. Asnacios, A.; Fartoux, L.; Romano, O.; Tesmoingt, C.; Louafi, S. S.; Mansoubakht, T.; Artru, P.; Poynard, T.; Rosmorduc, O.; Hebbar, M.; Taieb, J. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008, 112, 2733-2739.
64. Ramanathan, R. K.; Belani, C. P.; Singh, D. A.; Tanaka, M.; Lenz, H. J.; Yen, Y.; Kindler, H. L.; Iqbal, S.; Longmate, J.; Mack, P. C.; Lurje, G.; Gandour-Edwards, R.; Dancey, J.; Gandara, D. R. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother. Pharmacol. 2009, 64, 777-783.
65. Bekaii-Saab, T.; Markowitz, J.; Prescott, N.; Sadee, W.; Heerema, N.; Wei, L.; Dai, Z.; Papp, A.; Campbell, A.; Culler, K.; Balint, C.; O'Neil, B.; Lee, R. M.; Zalupski, M.; Dancey, J.; Chen, H.; Grever, M.; Eng, C.; Villalona-Calero, M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin. Cancer Res. 2009, 15, 5895-5901.
66. Konecny, G. E.; Pegram, M. D.; Venkatesan, N.; Finn, R.; Yang, G.; Rahmeh, M.; Untch, M.; Rusnak, D. W.; Spehar, G.; Mullin, R. J.; Keith, B. R.; Gilmer, T. M.; Berger, M.; Podratz, K. C.; Slamon, D. J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66, 1630-1639.
67. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E. H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366, 1527-1537.
68. Shepherd, F. A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabarbara, P.; Seymour, L. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353, 123-132.
69. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345.
70. Bonner, J. A.; Harari, P. M.; Giralt, J.; Azarnia, N.; Shin, D. M.; Cohen, R. B.; Jones, C. U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M. S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E. K.; Ang, K. K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567-578.
71. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1960-1966.
72. Galizia, G.; Lieto, E.; De Vita, F.; Orditura, M.; Castellano, P.; Troiani, T.; Imperatore, V.; Ciardiello, F. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007, 26, 3654-3660.
73. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
74. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
75. Wong, C. I.; Yap, H. L.; Lim, S. G.; Guo, J. Y.; Goh, B. C.; Lee, S. C. Lack of somatic ErbB2 tyrosine kinase domain mutations in hepatocellular carcinoma. Hepatol. Res. 2008, 38, 838-841.
76. Su, M. C.; Lien, H. C.; Jeng, Y. M. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett. 2005, 224, 117-121.
77. Karapetis, C. S.; Khambata-Ford, S.; Jonker, D. J.; O'Callaghan, C. J.; Tu, D.; Tebbutt, N. C.; Simes, R. J.; Chalchal, H.; Shapiro, J. D.; Robitaille, S.; Price, T. J.; Shepherd, L.; Au, H. J.; Langer, C.; Moore, M. J.; Zalcberg, J. R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359, 1757-1765.
78. Amado, R. G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D. J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; Patterson, S. D.; Chang, D. D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 1626-1634.
79. Challen, C.; Guo, K.; Collier, J. D.; Cavanagh, D.; Bassendine, M. F. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J. Hepatol. 1992, 14, 342-346.
80. Tannapfel, A.; Sommerer, F.; Benicke, M.; Katalinic, A.; Uhlmann, D.; Witzigmann, H.; Hauss, J.; Wittekind, C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52, 706-712.
81. Tsuda, H.; Hirohashi, S.; Shimosato, Y.; Ino, Y.; Yoshida, T.; Terada, M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn. J. Cancer Res. 1989, 80, 196-199.
82. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786-792.
83. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2, e73.
84. Kosaka, T.; Yatabe, Y.; Endoh, H.; Yoshida, K.; Hida, T.; Tsuboi, M.; Tada, H.; Kuwano, H.; Mitsudomi, T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 2006, 12, 5764-5769.
85. Yun, C. H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11, 217-227.
86. Roskoski, R., Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 2007, 356, 323-328.
87. Miura, H.; Miyazaki, T.; Kuroda, M.; Oka, T.; Machinami, R.; Kodama, T.; Shibuya, M.; Makuuchi, M.; Yazaki, Y.; Ohnishi, S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol. 1997, 27, 854-861.
88. Mise, M.; Arii, S.; Higashituji, H.; Furutani, M.; Niwano, M.; Harada, T.; Ishigami, S.; Toda, Y.; Nakayama, H.; Fukumoto, M.; Fujita, J.; Imamura, M. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996, 23, 455-464.
89. Su, Q.; Liu, Y. F.; Zhang, J. F.; Zhang, S. X.; Li, D. F.; Yang, J. J. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology 1994, 20, 788-799.
90. Boix, L.; Rosa, J. L.; Ventura, F.; Castells, A.; Bruix, J.; Rodes, J.; Bartrons, R. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 1994, 19, 88-91.
91. Selden, C.; Farnaud, S.; Ding, S. F.; Habib, N.; Foster, C.; Hodgson, H. J. Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours. J. Hepatol. 1994, 21, 227-234.
92. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
93. Abou-Alfa, G. K.; Schwartz, L.; Ricci, S.; Amadori, D.; Santoro, A.; Figer, A.; De Greve, J.; Douillard, J. Y.; Lathia, C.; Schwartz, B.; Taylor, I.; Moscovici, M.; Saltz, L. B. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006, 24, 4293-4300.
94. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-390.
95. Cheng, A. L.; Kang, Y. K.; Chen, Z.; Tsao, C. J.; Qin, S.; Kim, J. S.; Luo, R.; Feng, J.; Ye, S.; Yang, T. S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W. Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10, 25-34.
96. Yau, T.; Chan, P.; Ng, K. K.; Chok, S. H.; Cheung, T. T.; Fan, S. T.; Poon, R. T. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis Bendemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009, 115, 428-436.
97. Abou-Alfa, G. K.; Johnson, P.; Knox, J. J.; Capanu, M.; Davidenko, I.; Lacava, J.; Leung, T.; Gansukh, B.; Saltz, L. B. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010, 304, 2154-2160.
98. Prete, S. D.; Montella, L.; Caraglia, M.; Maiorino, L.; Cennamo, G.; Montesarchio, V.; Piai, G.; Febbraro, A.; Tarantino, L.; Capasso, E.; Palmieri, G.; Guarrasi, R.; Bianco, M.; Mamone, R.; Savastano, C.; Pisano, A.; Vincenzi, B.; Sabia, A.; D'Agostino, A.; Faiola, V.; Addeo, R. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother. Pharmacol. 2010, 66, 837-844.
99. Caraglia, M.; Giuberti, G.; Marra, M.; Addeo, R.; Montella, L.; Murolo, M.; Sperlongano, P.; Vincenzi, B.; Naviglio, S.; Prete, S. D.; Abbruzzese, A.; Stiuso, P. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011, 2, e150.
100. Hsu, C. H.; Shen, Y. C.; Lin, Z. Z.; Chen, P. J.; Shao, Y. Y.; Ding, Y. H.; Hsu, C.; Cheng, A. L. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J. Hepatol. 2010, 53, 126-131.
101. Tan, W. F.; Qiu, Z. Q.; Yu, Y.; Ran, R. Z.; Yi, B.; Lau, W. Y.; Liu, C.; Qiu, Y. H.; Feng, F. L.; Wang, J. H.; Yan, P. N.; Zhang, B. H.; Wu, M. C.; Luo, X. J.; Jiang, X. Q. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol. Sin. 2010, 31, 1643-1648.
102. Vitale, A.; Volk, M. L.; Pastorelli, D.; Lonardi, S.; Farinati, F.; Burra, P.; Angeli, P.; Cillo, U. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010, 51, 165-173.
103. Faivre, S.; Raymond, E.; Boucher, E.; Douillard, J.; Lim, H. Y.; Kim, J. S.; Zappa, M.; Lanzalone, S.; Lin, X.; Deprimo, S.; Harmon, C.; Ruiz-Garcia, A.; Lechuga, M. J.; Cheng, A. L. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009, 10, 794-800.
104. Zhu, A. X.; Sahani, D. V.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Catalano, O. A.; Sindhwani, V.; Blaszkowsky, L. S.; Yoon, S. S.; Lahdenranta, J.; Bhargava, P.; Meyerhardt, J.; Clark, J. W.; Kwak, E. L.; Hezel, A. F.; Miksad, R.; Abrams, T. A.; Enzinger, P. C.; Fuchs, C. S.; Ryan, D. P.; Jain, R. K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009, 27, 3027-3035.
105. Kanai, F.; Yoshida, H.; Tateishi, R.; Sato, S.; Kawabe, T.; Obi, S.; Kondo, Y.; Taniguchi, M.; Tagawa, K.; Ikeda, M.; Morizane, C.; Okusaka, T.; Arioka, H.; Shiina, S.; Omata, M. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2011, 67, 315-324.
106. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358, 2039-2049.
107. Siegel, A. B.; Cohen, E. I.; Ocean, A.; Lehrer, D.; Goldenberg, A.; Knox, J. J.; Chen, H.; Clark-Garvey, S.; Weinberg, A.; Mandeli, J.; Christos, P.; Mazumdar, M.; Popa, E.; Brown, R. S., Jr.; Rafii, S.; Schwartz, J. D. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 2008, 26, 2992-2998.
108. Zhu, A. X.; Blaszkowsky, L. S.; Ryan, D. P.; Clark, J. W.; Muzikansky, A.; Horgan, K.; Sheehan, S.; Hale, K. E.; Enzinger, P. C.; Bhargava, P.; Stuart, K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006, 24, 1898-1903.
109. Sun, W.; Sohal, D.; Haller, D. G.; Mykulowycz, K.; Rosen, M.; Soulen, M. C.; Caparro, M.; Teitelbaum, U. R.; Giantonio, B.; O'Dwyer, P. J.; Shaked, A.; Reddy, R.; Olthoff, K. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011, Epub ahead of print.
110. Hsu, C. H.; Yang, T. S.; Hsu, C.; Toh, H. C.; Epstein, R. J.; Hsiao, L. T.; Chen, P. J.; Lin, Z. Z.; Chao, T. Y.; Cheng, A. L. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer 2010, 102, 981-986.
111. Sahin, F.; Kannangai, R.; Adegbola, O.; Wang, J.; Su, G.; Torbenson, M. MTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. 2004, 10, 8421-8425.
112. Sieghart, W.; Fuereder, T.; Schmid, K.; Cejka, D.; Werzowa, J.; Wrba, F.; Wang, X.; Gruber, D.; Rasoul-Rockenschaub, S.; Peck-Radosavljevic, M.; Wacheck, V. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007, 83, 425-432.
113. Baba, H. A.; Wohlschlaeger, J.; Cicinnati, V. R.; Hilgard, P.; Lang, H.; Sotiropoulos, G. C.; Takeda, A.; Beckebaum, S.; Schmitz, K. J. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int. 2009, 29, 399-405.
114. Gedaly, R.; Angulo, P.; Hundley, J.; Daily, M. F.; Chen, C.; Koch, A.; Evers, B. M. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res. 2010, 30, 4951-4958.
115. Toso, C.; Meeberg, G. A.; Bigam, D. L.; Oberholzer, J.; Shapiro, A. M.; Gutfreund, K.; Ma, M. M.; Mason, A. L.; Wong, W. W.; Bain, V. G.; Kneteman, N. M. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007, 83, 1162-1168.
116. Toso, C.; Merani, S.; Bigam, D. L.; Shapiro, A. M.; Kneteman, N. M. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010, 51, 1237-1243.
117. Zimmerman, M. A.; Trotter, J. F.; Wachs, M.; Bak, T.; Campsen, J.; Skibba, A.; Kam, I. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008, 14, 633-638.
118. Park, J. W.; Finn, R. S.; Kim, J. S.; Karwal, M.; Li, R. K.; Ismail, F.; Thomas, M.; Harris, R.; Baudelet, C.; Walters, I.; Raoul, J. L. Phase II, Open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 2011, 17, 1973-1983.
119. Alberts, S. R.; Fitch, T. R.; Kim, G. P.; Morlan, B. W.; Dakhil, S. R.; Gross, H. M.; Nair, S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II north central cancer treatment group clinical trial. Am J Clin Oncol 2011, Epub ahead of print.
120. Lin, A. Y.; Brophy, N.; Fisher, G. A.; So, S.; Biggs, C.; Yock, T. I.; Levitt, L. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005, 103, 119-125.
121. Patt, Y. Z.; Hassan, M. M.; Lozano, R. D.; Nooka, A. K.; Schnirer, II; Zeldis, J. B.; Abbruzzese, J. L.; Brown, T. D. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005, 103, 749-755.
122. Schwartz, J. D.; Sung, M.; Schwartz, M.; Lehrer, D.; Mandeli, J.; Liebes, L.; Goldenberg, A.; Volm, M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferonalpha2a upon progression. Oncologist 2005, 10, 718-727.
123. Chiou, H. E.; Wang, T. E.; Wang, Y. Y.; Liu, H. W. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J. Gastroenterol. 2006, 12, 6955-6960.
124. Chuah, B.; Lim, R.; Boyer, M.; Ong, A. B.; Wong, S. W.; Kong, H. L.; Millward, M.; Clarke, S.; Goh, B. C. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol. 2007, 46, 234-238.
125. Yau, T.; Chan, P.; Wong, H.; Ng, K. K.; Chok, S. H.; Cheung, T. T.; Lam, V.; Epstein, R. J.; Fan, S. T.; Poon, R. T. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology 2007, 72 (Suppl 1), 67-71.
126. Pinter, M.; Wichlas, M.; Schmid, K.; Plank, C.; Muller, C.; Wrba, F.; Peck-Radosavljevic, M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur. J. Gastroenterol. Hepatol. 2008, 20, 1012-1019.
127. Zhu, A. X.; Fuchs, C. S.; Clark, J. W.; Muzikansky, A.; Taylor, K.; Sheehan, S.; Tam, K.; Yung, E.; Kulke, M. H.; Ryan, D. P. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 2005, 10, 392-398.
128. Ang, S. F.; Tan, S. H.; Toh, H. C.; Poon, D. Y.; Ong, S. Y.; Foo, K. F.; Choo, S. P. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. Am. J. Clin. Oncol. 2011, Epub ahead of print.
129. Ch'ang, H. J.; Hsu, C.; Chen, C. H.; Chang, Y. H.; Chang, J. S.; Chen, L. T. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. Int J. Radiat. Oncol. Biol. Phys. 2011, Epub ahead of print.
130. O'Neil, B. H.; Goff, L. W.; Kauh, J. S.; Strosberg, J. R.; Bekaii-Saab, T. S.; Lee, R. M.; Kazi, A.; Moore, D. T.; Learoyd, M.; Lush, R. M.; Sebti, S. M.; Sullivan, D. M. Phase II study of the mitogenactivated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2011, Epub ahead of print.
131. Savage, D. G.; Antman, K. H. Imatinib mesylate--a new oral targeted therapy. N. Engl. J. Med. 2002, 346, 683-693.
132. Borg, C.; Terme, M.; Taieb, J.; Menard, C.; Flament, C.; Robert, C.; Maruyama, K.; Wakasugi, H.; Angevin, E.; Thielemans, K.; Le Cesne, A.; Chung-Scott, V.; Lazar, V.; Tchou, I.; Crepineau, F.; Lemoine, F.; Bernard, J.; Fletcher, J. A.; Turhan, A.; Blay, J. Y.; Spatz, A.; Emile, J. F.; Heinrich, M. C.; Mecheri, S.; Tursz, T.; Zitvogel, L. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 2004, 114, 379-388.
133. Uziel, O.; Fenig, E.; Nordenberg, J.; Beery, E.; Reshef, H.; Sandbank, J.; Birenbaum, M.; Bakhanashvili, M.; Yerushalmi, R.; Luria, D.; Lahav, M. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomeraseexpressing cell lines. Br. J. Cancer 2005, 92, 1881-1891.
134. Vlahovic, G.; Ponce, A. M.; Rabbani, Z.; Salahuddin, F. K.; Zgonjanin, L.; Spasojevic, I.; Vujaskovic, Z.; Dewhirst, M. W. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br. J. Cancer 2007, 97, 735-740.
135. Ramadori, G.; Fuzesi, L.; Grabbe, E.; Pieler, T.; Armbrust, T. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anticancer Drugs 2004, 15, 405-409.
136. Eckel, F.; von Delius, S.; Mayr, M.; Dobritz, M.; Fend, F.; Hosius, C.; Schleyer, E.; Schulte-Frohlinde, E.; Schmid, R. M.; Lersch, C. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 2005, 69, 363-371.
137. Lin, A. Y.; Fisher, G. A.; So, S.; Tang, C.; Levitt, L. Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol 2008, 31, 84-88.
138. Becker, G.; Schmitt-Graeff, A.; Ertelt, V.; Blum, H. E.; Allgaier, H. P. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin. Oncol. (R. Coll. Radiol.) 2007, 19, 204-208.
139. Choueiri, T. K.; Schutz, F. A.; Je, Y.; Rosenberg, J. E.; Bellmunt, J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 2010, 28, 2280-2285.
140. Worns, M. A.; Schuchmann, M.; Duber, C.; Otto, G.; Galle, P. R.; Weinmann, A. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 2010, 79, 85-92.